Topos is building an AI-native drug discovery platform for intrinsically disordered proteins -- dynamic proteins implicated in diseases like Alzheimer's and prostate cancer. Our approach models protein ensembles rather than single static structures, unlocking previously "undruggable" targets.
Learn MoreToday we're releasing the first technical report on Topos-1, our all-atom foundation model for intrinsically disordered proteins (IDPs). Topos-1 generates physically realistic conformational ensembles for flexible proteins and does so at a speed that makes ensemble-level modeling practical in day-to-day research and drug discovery.
Read SummaryFounded by Berkeley and Stanford researchers, Topos unveils breakthrough foundation model for disordered proteins and partnering with Gladstone Institutes.
Read Press Release
